Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3739-3747

  Ciardiello, F ^a   Bianco, R ^a   Damiano, V ^a   Fontanini, G ^a   Caputo, R ^a   Pomatico, G ^a   De Placido, S ^a   Bianco, A R ^a   Mendelsohn, J ^a   Tortora, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; THIONUCLEOTIDES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033818695     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Autocrine secretion: Ten years later
2. Growth factors and cancer
3. Epidermal growth factor-related peptides and their receptors in human malignancies
4. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
5. Therapeutic application of anti-growth factor receptor antibodies
6. Type I receptor tyrosine kinases as targets for therapy in breast cancer
7. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
8. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain
9. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein
10. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: Selective protection of low EGFR-expressing cell lines by EGF
11. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors
12. Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα
13. 4,5-Bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity
14. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
15. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
16. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
17. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction
18. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
19. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
20. Tumor angiogenesis
21. Regulation of angiogenesis
22. The fibroblast growth factor family
23. Molecular and biological properties of the vascular endothelial growth factor family of proteins
24. The role of vascular endothelial growth factor in pathological angiogenesis
25. Clinical applications of research on angiogenesis
26. Clinical implications of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
27. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
28. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
29. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
30. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
31. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
32. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
33. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
34. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
35. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo
36. Adeno-associated virus-mediated delivery of antiangiogenic factors as antitumor strategy
37. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
38. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides
39. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A
40. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
41. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma
42. Evaluation of survival data and two new rank order statistics arising in its consideration
43. 8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer
44. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
45. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
46. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC)
47. Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC)
48. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
49. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
50. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer